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Biomarker analysis of Riboflavin status by DERiVE 
investigator Dr Liadhan McAnena, Ulster
Understanding the  
benefits of riboflavin
Professor Mary Ward introduces the DERiVE project, which is developing accessible riboflavin 
biomarkers for use in population studies globally, in order to investigate and address the functional 
and health consequences of sub-optimal riboflavin status
Could you begin 
by introducing 
yourself and your 
key research 
interests?
I am a Professor of 
Nutrition and Dietetics at Ulster University 
in Northern Ireland with a particular interest 
in the role of B-vitamins in cardiovascular 
disease. The interaction between 
B-vitamins and a common polymorphism
in the gene encoding the enzyme
methylenetetrahydrofolate reductase
(MTHFR) has been a main research focus in
recent years. Approximately 10-12 per cent
of adults in the UK and Ireland carry this
genetic risk factor (TT genotype in MTHFR),
which affects up to one in three adults in
some populations such as Mexico.
Previous work at Ulster has led to the novel 
discovery that the B-vitamin riboflavin 
appears to be an important modulator 
of blood pressure in individuals with this 
genetic predisposition for hypertension. 
Our current studies aim to understand 
the mechanisms linking this gene nutrient 
interaction with blood pressure.
Can you expand on the importance of 
riboflavin?
Riboflavin (vitamin B2) is a water-soluble 
B-vitamin that forms two important co-
enzymes – flavin mononucleotide (FMN) 
and flavin dinucleotide (FAD). Further to 
its well established role in health, recent 
novel work undertaken by our team at Ulster 
demonstrated that riboflavin plays a critical 
role in normalising blood pressure in people 
with the TT genotype in the gene encoding 
MTHFR.
Can you explain the benefits of good riboflavin 
status?
Riboflavin (in its co-factor forms FMN and 
FAD) is essential for oxidation-reduction 
reactions, so plays a critical role in numerous 
metabolic pathways in the body. Thus, better 
riboflavin status plays an important role in 
maintaining health throughout the lifecycle 
and has been associated with a decreased 
risk of a number of cancers and eye disorders, 
including age-related cataracts. A number 
of studies have also shown that riboflavin 
intervention benefits patients with specific, 
albeit relatively rare, metabolic disorders, 
although further work is required to confirm 
these findings. What is entirely novel however, 
is the work we have been leading in recent 
years, which shows a blood pressure lowering 
effect of riboflavin in adults with a common 
risk factor for hypertension.
The contribution of riboflavin to health is 
however, very much under-recognised at this 
time, and the evidence greatly lacking, due to 
the lack of accessible biomarkers to measure 
riboflavin status. The proposed project will 
address this gap by validating riboflavin 
biomarkers for use in the current proposal and 
in future nutrition research internationally.
Our Canadian partner from the University 
of British Columbia in Vancouver is 
developing accessible biomarkers for the 
assessment of riboflavin status. These will 
then be validated by measuring biomarker 
status in biological samples from nationally 
representative cohorts in Ireland and 
Canada, and samples from randomised 
controlled trials completed at Ulster. Their 
reliability as biomarkers of dietary intake 
will be determined using data from the Irish 
National Adult Nutrition Survey cohort led 
by our partners from University College Cork 
in Ireland.
What do you hope to achieve in relation to 
patients suffering from hypertension?
The health impact of optimising riboflavin 
could be considerable. For hypertensive 
patients identified with the TT genotype, 
riboflavin supplementation can offer a 
simple, non-drug treatment to effectively 
lower blood pressure. For sub-populations 
worldwide with this genetic risk factor, 
better riboflavin status (achieved through 
supplements or fortified foods) may 
prevent or delay the onset of high blood 
pressure. Thus, riboflavin, targeted at those 
with the TT genotype in MTHFR, offers 
a personalised treatment or preventative 
strategy for hypertension, one of the leading 
causes of mortality worldwide. High blood 
pressure (hypertension) has a number of 
adverse health consequences; in particular, 
it increases a person’s risk of stroke 
substantially. Lowering blood pressure has 
important health benefits: each 2mmHg 
decrease in systolic blood pressure is 
associated with a 10 per cent reduction 
in the risk of stroke. Thus, lowering blood 
pressure even by small amounts can be very 
beneficial. l
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Polyphenols for 
healthier ageing
Via the VALID project, Professor Helene McNulty is validating 
novel plasma biomarkers of polyphenol-rich foods and linking 
them with inflammation, metabolic health and cognition in an 
ageing European population
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Could you begin 
by introducing 
yourself? 
I am Director 
of the Nutrition 
Innovation Centre for Food and Health 
(NICHE) and Professor of Human Nutrition 
and Dietetics at Ulster University, Northern 
Ireland. The purpose of our research is to 
provide greater understanding of nutrition-
related health issues, to achieve impact 
through facilitating food and health policy, 
and to drive innovation activities.
Can you expand on your work with Professor 
Ward? 
A particular focus of our work involves 
conducting randomised controlled trials 
and observational studies to examine health 
outcomes in relation to nutritional factors, in 
healthy volunteers through the life cycle (from 
pregnancy and early life, to middle and older 
age) and in patient groups (such as those 
with cardiovascular disease, osteoporosis, 
cognitiive dysfunction and coeliac disease).
We were strategic in setting up The Centre 
of Excellence in Nutrition and Ageing 
(CENA) within NICHE at Ulster in 2010, to 
enhance our existing North-South of Ireland 
cross-border research activities in nutrition 
and ageing made possible through the 
Trinity, Ulster and Department of Agriculture 
(TUDA) Ageing Cohort study. This is an 
invaluable resource that is being further 
developed through the VALID project.
What are polyphenols and why do you 
believe, despite the current lack of 
biomarker evidence, that they may be 
beneficial in terms of maintaining cognitive 
function in older age? 
Polyphenols are among the most 
representative bioactive compounds, 
mainly present in plant-based foods, 
particularly grapes, nuts, berries, wine, tea 
and coffee. Polyphenols are not included 
in the category of micronutrients, as they 
are not essential for the maintenance 
of vital functions. However, several 
epidemiological and intervention studies 
show beneficial associations between long 
term intake of polyphenols and reduced 
incidence of cancer, chronic diseases and 
neurodegenerative processes.
In collaboration with experts in polyphenol 
biomarker analysis from the University of 
Parma, Italy, and our TUDA collaborators in 
Trinity College Dublin, the VALID project will 
identify and validate plasma-valerolactones 
as novel biomarkers that are modulated by 
dietary polyphenols and associated with 
cognitive function in later life.
What is the ultimate goal for both the 
DERiVE and VALID projects? 
The vision and goal of both the DERiVE 
and VALID projects is to promote 
scientific excellence through international 
collaboration across centres of excellence, 
which are allowing the collection and 
pooling of nutrition and health data in a 
uniform and standardised way. Furthermore, 
the sharing of expertise from across the 
participating countries allows cross-border 
mobility and training of researchers and 
will facilitate the timely dissemination and 
translation of our research results to inform 
public health practice and policy across 
Europe, and indeed globally. 
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Impact Objectives
• Gain a better understanding of the role of nutrition in health by developing and validating novel 
biomarkers of dietary exposure in transnational research studies 
• Grow capacity, capability and sustainable transnational partnerships in nutrition and health research,  
led by a UK partner in collaboration with partners in Canada, Republic of Ireland and Italy 
• Demonstrate the functional and metabolic effects of optimal riboflavin status on cardiovascular health 
(DERiVE project), and of dietary polyphenols on the ageing brain (VALID project)
Nourishing nutrition and 
health research
Two innovative projects underway at Ulster University, Northern Ireland, are inextricably linked by 
their shared focus on improving nutrition with implications for health across the lifespan
Nutrition is of the utmost importance, 
particularly given the phenomenon of 
ageing populations worldwide. The lack of 
validated nutritional biomarkers in some 
cases however, is hampering the ability of 
researchers to investigate the roles and 
health benefits of certain nutrients.
Two projects underway at Ulster University, 
Northern Ireland, headed up by Professors 
Mary Ward and Helene McNulty, 
respectively, are:
• Development of riboflavin biomarkers to 
relate dietary sources with status, gene-
nutrient interactions and validated health 
effects in adult cohorts (DERiVE).
Project partners: Ulster University (Lead 
Institution), University of British Columbia 
(Canada) and University College Cork 
(Ireland).
• Valerolactones and healthy ageing: 
Linking dietary factors, nutrient biomarkers, 
metabolic status and inflammation with 
cognition in older adults (VALID).
Project partners: Ulster University (Lead 
Institution), Trinity College Dublin (Ireland) 
and University of Parma (Italy).
DERIVE AND VALID
The two projects are closely related and 
share similar goals, as Ward and McNulty 
explain: ‘By linking these projects, it is our 
intention to build capacity and capability 
in nutrition research and to extend the 
international collaborations made possible 
through this JPI initiative.’
The DERiVE project will develop accessible 
riboflavin biomarkers for use in population 
surveys globally, and demonstrate important 
functional, gene-nutrient and health effects 
of optimal riboflavin status.
The VALID project will validate novel 
biomarkers of polyphenol-rich foods and 
link them with inflammation, metabolic 
health and cognition in an ageing European 
population.
Both projects are in their first year and will 
conclude at the end of 2019.
HEALTH IMPACTS
The goal of DERiVE is to promote health 
and wellness in adults, with evidence that 
sub-optimal riboflavin status may be a much 
greater global health risk than is currently 
recognised. ‘Riboflavin has an important 
role in one-carbon metabolism where it 
interacts with other relevant nutrients 
(folate, vitamin B12 and vitamin B6),’ Ward 
explains. VALID will develop and evaluate 
novel biomarkers that reflect dietary intakes 
of polyphenols (abundant in foods such as 
tea, cocoa, grapes, nuts and berries). ‘Our 
research will also investigate the biological 
mechanisms that could link dietary 
polyphenols with cognitive health as people 
age,’ McNulty adds.
Indeed, both projects are concerned with 
health impacts on ageing populations, as 
the researchers explain: ‘There is an urgent 
need to identify public health nutrition 
strategies aimed at promoting better health 
throughout the lifecycle for healthy ageing. 
We are committed to generating the highest 
quality research to support evidence-based 
policies to meet the nutrition and health 
needs of older populations globally.’
GROWING TRANSNATIONAL LINKS
Both projects are progressing well and, 
looking ahead, Ward and McNulty hope 
to expand these research areas. ‘These 
projects have enabled us to develop strong 
international collaborations in nutrition 
and health and we aim to not only grow 
our capacity, but also the capabilities of the 
teams. It is also intrinsic that the transnational 
partnerships we are developing in Canada, the 
Republic of Ireland and Italy, are sustainable.’
The DERiVE and VALID projects are  
funded under the JPI Co-funded ERA-HDHL 
joint call ‘Biomarker for nutrition and 
health’. In line with the JPI’s ‘A healthy 
diet for a healthy life’ vision to support 
quality, translational, collaborative 
research, the goal of both projects is to 
promote scientific excellence through 
international collaborations. Go to: www.
healthydietforhealthylife.eu/index.php/joint-
actions/era-hdhl-ja
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